Jennifer Butler has been appointed chief commercial officer, Tessa Therapeutics. In her new role, she will be responsible for driving the global launch and commercialization strategy of Tessa’s advanced T cell therapy pipeline, including the company’s lead product, TT10, which is currently in Phase III development for the treatment of nasopharyngeal carcinoma. Ms. Butler will be based in the U.S. and will be leading the expansion of the company’s business operations there. Ms. Butler ha...